Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares OutstandingShares OutstandingShort-Term Debt issuancesShort-Term Debt repayments
Ratios

China Pharma Holdings (CPHI) Long-Term Debt Issuances (2016 - 2025)

China Pharma Holdings filings provide 14 years of Long-Term Debt Issuances readings, the most recent being $7573.0 for Q4 2025.

  • On a quarterly basis, Long-Term Debt Issuances rose 11.33% to $7573.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $261070.0, a 854.45% increase, with the full-year FY2025 number at $261070.0, up 854.45% from a year prior.
  • Long-Term Debt Issuances hit $7573.0 in Q4 2025 for China Pharma Holdings, up from -$44176.0 in the prior quarter.
  • In the past five years, Long-Term Debt Issuances ranged from a high of $626188.0 in Q2 2021 to a low of -$47241.0 in Q1 2022.
  • Median Long-Term Debt Issuances over the past 5 years was $7018.0 (2022), compared with a mean of $84158.7.
  • The widest YoY moves for Long-Term Debt Issuances: up 4145.27% in 2025, down 745.56% in 2025.
  • China Pharma Holdings' Long-Term Debt Issuances stood at $11170.0 in 2021, then tumbled by 38.69% to $6848.0 in 2022, then grew by 1.42% to $6945.0 in 2023, then dropped by 2.06% to $6802.0 in 2024, then grew by 11.33% to $7573.0 in 2025.
  • The last three reported values for Long-Term Debt Issuances were $7573.0 (Q4 2025), -$44176.0 (Q3 2025), and $290886.0 (Q2 2025) per Business Quant data.